Keywords: Teijin, Astellas, Febuxostat, Gout, Southeast Asia, India
Teijin and Astellas expand collaboration on gout drug febuxostat
Article | 12 August 2011
Japanese drugmakers Teijin Pharma (TYO: 3401 and Astellas Pharma (TKO:4503) have entered into an exclusive distribution agreement for febuxostat (development code: ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
